SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Josh C. Pleasure, M.D. who wrote (147)6/8/1997 2:34:00 PM
From: M. LaMancha   of 371
 
Dr. Pleasrue -- I'd appreciate your opinion about whther Leukoscan will meet a major need in the marekt. As I undestand it, cardiology accounts for about 50% of procedure volume and bones cans for about another 30%. That leaves just 20% for the many other procedures. What percentage of total scans do white blood cells account for, in your opinion; and might the use of Leukoscan increse the usage of this type of study. If it doesn't, is there enough money to be made to make Leukoscan into a major provider of revenue?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News